Announcement: New CEO in Biomega

Biomega Group announced that Sten Estrup has been appointed as its new Chief Executive Officer. He will assume the position on September 1 2019.

Sten Estrup comes with 25 years of experience from across the food and health industry in executive roles in operations, sales, marketing and commercial development. He leaves the position of Executive Vice President of Asia Pacific & Latin America at Chr. Hansen, a leading bioscience company that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries, to join Biomega.

“I am honored to join Biomega and work with the team, partners, customers and the owner AMERRA to release the true potential of Biomega’s leading technology for human-grade ingredients. The world of food production and agriculture is waiting for Biomega’s technology and expertise to help improve productivity and produce more with less,” says Estrup. “Biomega is well positioned to leverage the emerging demand for natural science-backed bioactive peptides to the nutraceutical and functional food industry,” he adds.

Former CEO Jørgen Horntvedt has stepped down and will pursue other opportunities outside of Biomega. Thomas Samdal, the CFO of Biomega Group, has taken on the role as interim CEO until Estrup commences the position.

“We are very fortunate to have someone of Sten’s caliber and international experience to lead Biomega. Biomega is at a transformational moment and Sten’s leadership will ensure successful implementation of our strategy, capture the international market opportunities and significantly scale Biomega. Sten is customer focused and has a proven track record of building businesses and executing growth market strategies,” says Thor Talseth, Chairman of Biomega Group and head of Private Equity with AMERRA Capital. “I am grateful for the dedication Jørgen has shown in Biomega. I am also glad that Thomas has accepted the positionas interim CEO, a role I know he will execute very well.”

Contact information

Thor Talseth (chairman of the board):, +1 929 202 3090
Thomas Samdal (interim CEO):, +47 93 66 46 06

About AMERRA Capital

AMERRA Capital Management, LLC is a New York-based alternative asset management firm with more than $2.0 billion in assets under management. AMERRA is providing strategic capital to growth-oriented agri businesses in the Americas and Western Europe. Since its inception in 2009, AMERRA has invested more than $4.0 billion.

About Biomega Group

The Biomega Group aspires to become the leading partner for innovative high-quality ingredients to the health & nutrition industry. Biomega’s business model is fully sustainable and uses proprietary biotech to transform high quality raw material into premium food and feed ingredients. In its modern food grade biorefinery in Norway, Biomega produces hydrolyzed salmon proteins (salmon peptides), salmon meal and salmon oil. Biomega invests continuously in R&D to ensure best-in-class technology and respond to customers’ needs, including traceability and sustainability.